Press release from Companies
Publicerat: 2019-04-26 09:10:00
With respect to Spotlight Stock Market’s decision on 25 April 2019 to halt trading in NextCell Pharma AB"s share, the stock market has, in accordance with its regulations, ordered the company to comment on the trading halt.
Discussions are currently underway between the boards of NextCell Pharma AB and Idogen AB regarding a potential merger. The structure being discussed would entail that NextCell Pharma AB makes a bid for all of the shares in Idogen AB and in turn will offer its own shares as a means of payment. At the time of the press release, the dialogue between the companies has only just begun and NextCell Pharma AB"s Board of Directors intends to publish more information some time during the forthcoming week. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26 April 2019. Stay up to date with the latest development in NextCell Pharma LinkedIn: https://www.linkedin.com/company/15255207/ Twitter: https://twitter.com/NextCellPharma For more information about NextCell Pharma AB, please contact: Mathias Svahn, CEO Sofia Fredrikson, CFO Phone: 08-735 5595 E-mail: info@nextcellpharma.com About NextCell Pharma AB: Stem cells are expected to change the way how many of today"s life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB"s proprietary method. In addition, the company has a service called Cellaviva, Sweden"s first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.
